FDA Acknowledges Efficacy of Rexlemestrocel-L for Chronic Back Pain, Supports BLA Filing

summarizeSummary

Mesoblast received positive feedback from the FDA regarding its rexlemestrocel-L therapy for chronic low back pain, with the agency acknowledging efficacy data and supporting a BLA filing.

check_boxKey Events

• FDA Efficacy Acknowledgment

  The FDA acknowledged that the effects on pain intensity for rexlemestrocel-L appear to favor the active arm in the Phase 3 trial (MSB-DR003).

• Efficacy Support for BLA

  The FDA confirmed that a clinically meaningful reduction in pain intensity at 12 months can support product efficacy for a Biologics License Application (BLA).

• Opioid Reduction Labeling Potential

  The FDA stated that robust results on opioid reduction from the trial could be included in the Clinical Studies section of the product labeling, highlighting the therapy's potential to address the opioid crisis.

• Confirmatory Phase 3 Progress

  The second randomized controlled Phase 3 trial (MSB-DR004) is over 50% enrolled and is expected to complete its 300-patient target within three months.

auto_awesomeAnalysis

The FDA's positive feedback on Mesoblast's rexlemestrocel-L for chronic discogenic low back pain significantly de-risks the path to a Biologics License Application (BLA). The agency's acknowledgment that the Phase 3 trial data supports product efficacy and that opioid reduction results could be included in the product labeling are strong indicators of potential approval and commercial success. This development provides clarity and confidence regarding the regulatory strategy for a key pipeline asset.